SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs upcoming Phase 3 REGAL trial results for its GPS leukemia treatment dominate discussion, with topline data expected this month after the trial reached its final analysis milestone. Traders are split between optimism about a potential breakthrough and concern over the binary trial outcome, while sharp price swings have fueled debate about selling pressure and alleged short-term manipulation.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA review of ivonescimab for EGFR-mutated lung cancer is driving a binary-outcome debate over approval versus a possible rejection or request for more evidence. Bulls point to strong progression-free-survival results and encouraging survival trends, while bears focus on the FDAs stated need for statistically significant overall-survival evidence; recent weakness has also prompted speculation about a negative outcome, though traders say price action alone is not proof.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian shares are under pressure amid a broader pullback in EV and growth stocks, with traders also focused on the stocks persistent weakness and concerns about cash burn, profitability, and management. Some blame short sellers or trading dynamics, while bulls point to R2 progress and recent operating results as reasons for optimism; those explanations remain debated.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unitys strong Q3 resultsits first GAAP-profitable quarter, rapid growth in its Vector ad platform, and upbeat outlookhave fueled a sharp rebound and discussion of a possible turnaround. Reported takeover talks with Silver Lake and Saudi Arabias PIF add speculation, with traders debating whether the discussed valuation would undervalue the company or whether a deal will happen at all.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQs sharp after-hours drop drew attention as traders linked the move to the FAAs nationwide ground stop after communications problems, while speculation about a cyberattack or AI involvement remained unverified. The discussion also reflected wider pressure on tech and AI stocks tied to uncertainty around Nvidia, with traders divided between seeing the selloff as an overreaction and expecting further weakness.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

Reports of an FAA nationwide ground stop tied to air-traffic-control communications problems are drawing attention to AAL, with traders discussing possible departure delays and rerouting. Some characterize the disruption as brief, while speculation about its cause remains unverified.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs abrupt departure and the unresolved CEO succession are driving concern, with traders divided between those calling for his return and those worried about leadership continuity and scrutiny of Nvidias China-related chip sales. Upcoming earnings are another focus, but bullish bets on results and dip-buying compete with fears that uncertainty and further fallout could weigh on the stock.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is selling off after lowering its revenue outlook amid delays activating third-party data-center capacity, prompting analyst concerns about execution and near-term growth; weakness across AI and neocloud stocks, alongside uncertainty around Nvidia, is adding pressure. Traders are split between viewing the delays and higher spending as serious risks and seeing them as temporary setbacks in a business with strong AI demand.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUMs strong third-quarter results and rapid growth in its Quake AI GPU-cloud business are driving attention as the companys AI-infrastructure pivot gains traction. Bulls point to improving operations and the Anthropic-linked expansion, while skeptics focus on losses, cash needs and financing risks; short-squeeze claims remain speculation.

HawKeye 360, Inc. engages in the provision of defense technology. It offers spectrum monitoring, maritime intelligence, air defence radar monitoring, GNSS interference detection, and communications mapping. Its costumers include a wide range of commercial, government and international entities. The company was founded by Charles T. Clancy, Robert G. McGwier, Chris DeMay and John Serafini in 2015 and is headquartered in Herndon, VA.

HawkEye 360 Inc.

HAWK is drawing attention after reporting record third-quarter revenue and raising its full-year outlook, with traders also highlighting international growth, contract demand, and plans for lower-cost satellites. The community reaction is broadly bullish on the results and rally, though claims of institutional accumulation and further upside remain speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eli Lilly Stock Eyes Best Month This Year As Cholesterol, Obesity Drug Tailwinds Build

Equity

LLY's stock is still down year-to-date as AI-driven narratives have captured the bulk of investor attention and capital in 2026.

Neutral Sentiment

<ul class="summary-bullets"><li>LLY is just 6.5% away from its all-time high, which made it the first healthcare company in the world to reach a $1 trillion market cap.</li><li>Late Monday, Lilly released encouraging Phase 1b trial data for Verve-102, an experimental gene-editing treatment designed to permanently lower LDL cholesterol with a single infusion.</li><li>Wall Street consensus for LLY is 'Strong Buy' among 31 analysts, with an average price target implying roughly 13% upside from current levels.</li></ul>Eli Lilly shares are on track for their best month of 2026, up 14% as May draws to a close, lifted by a pair of drug developments that underscore the company's expanding ambitions beyond obesity and into cardiovascular disease.<h1 class="st-heading-1">Lilly's Cholesterol Breakthrough</h1>Late Monday, Lilly released interim Phase 1b trial data for Verve-102, an experimental medicine that uses gene editing to permanently lower LDL ("bad" cholesterol), potentially from a single infusion.Rather than a daily pill or a recurring injection, Verve-102 is designed to make a one-time edit to the PCSK9 gene in liver cells. PCSK9 is a protein that interferes with the liver's ability to clear LDL from the bloodstream; by blocking it, the treatment aims to reduce cholesterol levels durably with a single dose.In an interim analysis of 35 participants, the results were notable. PCSK9 protein levels fell by 51% to 88% across dose levels, and LDL cholesterol dropped by up to 62% at the highest dose, with reductions lasting up to 18 months after a single treatment. The trial focused on two high-risk patient groups: people with heterozygous familial hypercholesterolemia, an inherited condition causing dangerously elevated cholesterol from birth, and those with premature coronary artery disease.<h1 class="st-heading-1">Lilly Rides Obesity Drug Wave With Mounjaro</h1>Lilly is also riding the fastest-growing pharmaceutical category in history. From a near-standing start in 2021, the four leading GLP-1 weight-loss drugs — Mounjaro, Ozempic, Zepbound, and Wegovy — are on pace to generate more than $100 billion in sales this year. Lilly's Mounjaro has emerged as the standout, surpassing Merck's cancer blockbuster Keytruda to become the world's best-selling drug last quarter.<img src="https://news.stocktwits-cdn.com/Eli_Lillys_Mounjaro_Is_The_New_Blockbuster_Drug_jpg_84d35127c2.webp" alt="Eli_Lillys_Mounjaro_Is_The_New_Blockbuster_Drug.jpg">Last week,&nbsp;<a href="https://stocktwits.com/symbol/LLY">LLY</a> received a fresh wave of analyst upgrades following trial readouts for retatrutide, Lilly's experimental next-generation obesity drug, which helped patients lose more than 28% of their body weight over 18 months.&nbsp;According to summaries on The Fly, RBC Capital called the results "a clean win," citing a strong safety profile and best-in-class efficacy across all doses. The firm is modeling a retatrutide launch in 2027, with 2030 sales of $4.9 billion and 2034 sales of $11.0 billion, assigning a 70% probability of success. Truist said the data set a new benchmark for anti-obesity medications and would support approval for patients not adequately served by existing treatments.<h1 class="st-heading-1">Eli Lilly Valuation And Technical Levels</h1>Lilly is just 6.5% below its all-time high in November 2025, the same level at which it briefly became the first healthcare company in history to reach a $1 trillion market capitalization. The stock has maintained its momentum since forming a golden cross in early November, when the 50-day moving average crossed above the 200-day moving average.<img src="https://news.stocktwits-cdn.com/koyfin_20260526_101102725_png_7e57b1defa.webp" alt="koyfin_20260526_101102725.png">Still, the valuation warrants attention. LLY trades at a forward price-to-earnings ratio of 28x, above the&nbsp;<a href="https://stocktwits.com/symbol/SPY">S&amp;P 500</a>'s 21x and well above&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk</a>'s 14x. Its RSI of 68.3 sits in borderline overbought territory.According to Koyfin, Wall Street remains firmly bullish on LLY overall, with a 'Strong Buy' consensus among 31 analysts and an average price target of roughly $1,211, implying about 13% upside from current levels.<h1 class="st-heading-1">What Retail Thinks About LLY Stock</h1>On Stocktwits, sentiment for LLY has shifted from 'bearish' a year ago to 'neutral' at the last close, suggesting caution persists among retail traders despite the strong fundamentals. Engagement for the stock remains robust: followers have jumped 25%, and message volume has surged 250% over the past year."LP(a) is the next frontier in cardiovascular care. All hereditary and there is nothing to treat it at the moment. This will be huge,"&nbsp;<a href="https://stocktwits.com/Rmccall/message/654327691">said</a> one bullish user following the latest cholesterol trial.Another&nbsp;<a href="https://stocktwits.com/LLYBULL/message/654313361">expects</a> LLY to "double within next 3 years!"Interestingly, the stock is still down about 0.5% year-to-date following nine consecutive years of strong gains, as AI-driven narratives have captured the bulk of investor attention and capital in 2026. However, Goldman Sachs&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/05/25/want-to-hop-off-the-ai-trade-goldman-says-buy-these-stocks-that-have-nothing-to-do-with-it.html">counts</a> LLY among its top picks specifically for its low sensitivity to AI trade rotation and U.S. economic uncertainty.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/default/5/bb-sidu-rgti-stocks-lead-last-week-wildest-upswings-what-happened/cZgapUQRepf">BB, SIDU, RGTI Stocks Lead Last Week’s Wildest Upswings: Here's What Happened</a>

In this photo illustration, a person holds a smartphone displaying the logo of Eli Lilly and Company on August 7, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Lilly(Eli) & Co

Novo Nordisk A/S

Obesity ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

SLIM News